Mizuho Securities Reiterates a Buy Rating on Supernus Pharmaceuticals (SUPN)


In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Supernus Pharmaceuticals (SUPN), with a price target of $63. The company’s shares closed yesterday at $37.85.

Rivkind Koffler commented:

“We believe the Day failed to rally SUPN because of the cautious body language around the SPN-810 asset in impulsive aggression. We believe investors may avoid the pending Phase III SPN-810 impulsive aggression read-out in 2H:19 (next big catalyst/clearing event for the stock) because mgmt. highlighted the pioneering aspects of its program, and its unprecedented reliance on daily caregiver data reports. We reiterate our Buy rating as SUPN trades below our $47 bear case valuation which assigns no value to SPN-810.”

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 7.1% and a 41.2% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.

Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $60.20, which is a 59.0% upside from current levels. In a report issued on April 11, Jefferies also maintained a Buy rating on the stock with a $58 price target.

See today’s analyst top recommended stocks >>

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $25.89 million. In comparison, last year the company had a net profit of $26.35 million.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SUPN in relation to earlier this year. Last month, John Siebert, a Director at SUPN bought 16,179 shares for a total of $137,806.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts